Anat Naschitz
Supervisory board member
Ms. Anat Naschitz is a life science investor and entrepreneur with over three decades of experience spanning biotech, pharmaceuticals, computational R&D, digital health, and medical devices across multiple therapeutic areas and stages. Throughout her career, Ms. Naschitz has founded companies and guided them to success through active leadership and strategic board participation in both public and private entities.
She is currently co-founder and CEO of 9xchange, a computational company creation engine leveraging artificial intelligence and machine learning to optimize biopharmaceutical assets. Ms. Naschitz co-founded and co-led OrbiMed Israel, part of the $17 billion global healthcare investment firm, and previously worked with Apax, a €65 billion private equity firm specializing in healthcare investments.
Among the companies she has helped shape and served as a board member is 89bio (Nasdaq: ETNB), which she founded as a pharmaceutical spin-out, led to its IPO within 18 months, and continued to support. In September 2025, Roche announced an agreement to acquire 89bio for up to $3.5 billion, underscoring the value and impact of 89bio’s innovation in metabolic and liver disease therapeutics.
Ms. Naschitz also serves on the board of Azura Ophthalmics, ForSight Vision 6, TytoCare, and MDClone, and was previously an Associate Partner at McKinsey in London. She holds an MBA from INSEAD and an LL.B. from Tel Aviv University.